Gossye Helena, Engelborghs Sebastiaan, Van Broeckhoven Christine, van der Zee Julie
VIB Center for Molecular Neurology, VIB;, Neurogenetics Lab, Institute Born-Bunge;, Department of Biomedical Sciences, University of Antwerp;, Department of Neurology and Memory Clinic, Hospital Network Antwerp, Antwerp, Belgium
Department of Neurology, University Hospital Antwerp, Edegem, Belgium
frontotemporal dementia and/or amyotrophic lateral sclerosis (-FTD/ALS) is characterized most often by frontotemporal dementia (FTD) and upper and lower motor neuron disease (MND); however, atypical presentations also occur. Age at onset is usually between 50 and 64 years (range: 20-91 years) irrespective of the presenting manifestations, which may be pure FTD, pure amyotrophic lateral sclerosis (ALS), or a combination of the two phenotypes. The clinical presentation is highly heterogeneous and may differ between and within families, causing an unpredictable pattern and age of onset of clinical manifestations. The presence of MND correlates with an earlier age of onset and a worse overall prognosis.
DIAGNOSIS/TESTING: The diagnosis of -FTD/ALS is established in a proband with suggestive findings and a heterozygous abnormal GC (GGGGCC) hexanucleotide repeat expansion in identified by molecular genetic testing.
Care is often provided by a multidisciplinary team that includes a neurologist, specially trained nurses, pulmonologist, speech therapist, physical therapist, occupational therapist, respiratory therapist, nutritionist, psychologist, social worker, and genetic counselor. Routine follow up by multidisciplinary specialists to monitor neurologic findings, mobility and activities of daily living, psychiatric/behavioral manifestations, nutrition and safety of oral feeding, respiratory and bladder function, and needs of affected individuals and care providers for psychosocial support.
-FTD/ALS is inherited in an autosomal dominant manner. Almost all individuals diagnosed with -FTD/ALS inherited a GC repeat expansion from a heterozygous parent. In most families the heterozygous parent is affected; however, a heterozygous parent may not have clinical manifestations of the disorder due to age-dependent reduced penetrance. Each child of an individual with -FTD/ALS has a 50% chance of inheriting the GC repeat expansion. Once a GC repeat expansion has been identified in an affected family member, prenatal and preimplantation genetic testing for the presence of the GC repeat expansion are possible. (Note: The presence of a GC repeat expansion cannot predict the disease course in any given individual.)
额颞叶痴呆和/或肌萎缩侧索硬化(-FTD/ALS)最常表现为额颞叶痴呆(FTD)以及上下运动神经元病(MND);不过,非典型表现也会出现。发病年龄通常在50至64岁之间(范围:20 - 91岁),与呈现的临床表现无关,临床表现可能为单纯的FTD、单纯的肌萎缩侧索硬化(ALS)或两种表型的组合。临床表现高度异质性,在不同家庭以及同一家庭内部可能有所不同,导致临床表现的模式和发病年龄不可预测。MND的存在与发病年龄较早及总体预后较差相关。
诊断/检测:在先证者中,若有提示性发现且经分子遗传学检测确定存在杂合异常GC(GGGGCC)六核苷酸重复扩增,则可确立-FTD/ALS的诊断。
通常由多学科团队提供护理,该团队包括神经科医生、经过专门培训的护士、肺科医生、言语治疗师、物理治疗师、职业治疗师、呼吸治疗师、营养师、心理学家、社会工作者和遗传咨询师。多学科专家进行常规随访,以监测神经学检查结果、活动能力和日常生活活动、精神/行为表现、经口喂养的营养和安全性、呼吸及膀胱功能,以及受影响个体和护理提供者对心理社会支持的需求。
-FTD/ALS以常染色体显性方式遗传。几乎所有被诊断为-FTD/ALS的个体都从杂合子父母那里遗传了GC重复扩增。在大多数家庭中,杂合子父母会受影响;然而,由于年龄依赖性的外显率降低,杂合子父母可能没有该疾病的临床表现。患有-FTD/ALS的个体的每个孩子都有50%的机会遗传GC重复扩增。一旦在受影响的家庭成员中确定存在GC重复扩增,就可以进行产前和植入前基因检测以确定是否存在GC重复扩增。(注意:GC重复扩增的存在无法预测任何特定个体的疾病进程。)